Through the Chroma Foundation, Chroma ATE donated its MagXtract® 3200 Automated Nucleic Acid Extraction and PCR Setup System to the Good Liver Foundation to support the foundation's alcohol metabolizing enzyme gene testing program. By providing a mature and highly automated molecular testing solution, Chroma ATE aims to facilitate the implementation of testing workflows while supporting risk assessment and health management initiatives.

Turning Vision into Action: Supporting Preventive Healthcare

According to Chroma ATE, this donation originated from a meaningful and practical exchange with the Good Liver Foundation. During the discussion, Professor Jin-Chuan Sheu, Chairman of the Good Liver Foundation, shared the vision behind promoting alcohol metabolizing enzyme gene testing—to improve testing workflow efficiency, provide valuable references for public health decision-making and risk assessment, and integrate preventive healthcare into everyday health management. Inspired by this vision, Chroma ATE believes that if its mature automated testing technology can make a meaningful contribution, the company has a responsibility to support the initiative through concrete action. Therefore, Chroma ATE made this donation through the Chroma Foundation and will continue to serve as a long-term technology partner in advancing the program.

Designed for Workflow Integrity and Highly Automated Medium-to-Low Throughput Testing

The MagXtract 3200 is an automated nucleic acid extraction system developed by Chroma ATE with a core focus on workflow integrity and high-level automation. Capable of processing up to 32 samples per run, the system delivers both efficiency and consistency, making it particularly suitable for medium-to-low throughput laboratories requiring highly automated workflows, including hospital laboratories, testing centers, and reagent development and validation environments.

Integrated Nucleic Acid Extraction and Automated Liquid Handling for an End-to-End Sample Preparation Workflow

The MagXtract 3200 integrates nucleic acid extraction and automated liquid handling into a single platform, creating a continuous and highly automated sample preparation workflow. Once samples are loaded, the system automatically performs key procedures—including sample dispensing, reagent distribution, and nucleic acid extraction—without manual intervention. After nucleic acid extraction is completed, the built-in automated liquid handling module precisely transfers the extracted DNA and automatically prepares the PCR reaction mixture by dispensing the required reagents. This integrated workflow significantly reduces manual sample transfers, minimizing the risks of human error and cross-contamination. By consolidating multiple instruments and manual procedures into a single automated platform, the MagXtract 3200 improves operational efficiency, consistency, and reproducibility. As a molecular testing sample preparation system, the MagXtract 3200 enhances laboratory workflow efficiency and quality consistency through automated nucleic acid extraction and PCR reaction setup. To ensure compliance with applicable regulations governing diagnostic testing and clinical interpretation, the system is designed exclusively for laboratory sample preparation and does not provide disease diagnosis or clinical treatment recommendations. All diagnostic testing and medical interpretations remain the responsibility of qualified healthcare professionals in accordance with relevant regulations.

Open Platform Supporting Diverse Reagents and Laboratory Developed Tests (LDTs)

In addition to its highly automated workflow, the MagXtract 3200 features an open platform architecture, allowing compatibility with a wide range of commercially available nucleic acid extraction and PCR reagents. This flexibility enables laboratories to select reagent combinations that best suit their specific application requirements. The open-platform design also makes the MagXtract 3200 an ideal automation platform for reagent developers, enabling them to efficiently integrate existing or newly developed assays into automated sample preparation workflows while improving workflow stability and reproducibility. For hospitals and laboratories developing Laboratory Developed Tests (LDTs), the MagXtract 3200 provides a flexible and reliable automation platform that supports the establishment and expansion of customized testing workflows while helping standardize laboratory processes within existing regulatory and quality management frameworks.

Enabling Technology to Create Meaningful Social Impact

Chroma ATE emphasized that supporting this donation through the Chroma Foundation reflects the company's long-term commitment to social responsibility and public welfare. By placing mature automated molecular testing technology in the hands of a professional and mission-driven organization such as the Good Liver Foundation, Chroma aims to ensure that advanced technology delivers tangible value beyond the laboratory and directly addresses real-world healthcare needs. Looking ahead, Chroma ATE will continue investing in the research and development of automated molecular testing technologies while collaborating with healthcare institutions, research organizations, and nonprofit partners to advance preventive medicine and become a long-term partner in promoting the digitalization and automation of public health testing workflows.

▲ Group photo from the donation ceremony. From left to right: Liang-Yu Chen, Director-General of the National Health Insurance Administration; Leo Huang, Chairman of Chroma ATE; Professor Jin-Chuan Sheu, Chairman of the Liver Disease Prevention & Treatment Research Foundation; Dr. Hsiao-Ching Nien, Executive Director of the Liver Disease Prevention & Treatment Research Foundation.